Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma

Gangadhara R. Sareddy, Xiaonan Li, Jinyou Liu, Suryavathi Viswanadhapalli, Lauren Garcia, Aleksandra Gruslova, David Cavazos, Mike Garcia, Anders M. Strom, Jan Ake Gustafsson, Rajeshwar Rao Tekmal, Andrew Brenner, Ratna K. Vadlamudi

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


Glioblastomas (GBM), deadly brain tumors, have greater incidence in males than females. Epidemiological evidence supports a tumor suppressive role of estrogen; however, estrogen as a potential therapy for GBM is limited due to safety concerns. Since GBM express ERβ, a second receptor for estrogen, targeting ERβ with a selective agonist may be a potential novel GBM therapy. In the present study, we examined the therapeutic effect of the selective synthetic ERβ agonist LY500307 using in vitro and in vivo GBM models. Treatment with LY500307 significantly reduced the proliferation of GBM cells with no activity on normal astrocytes in vitro. ERβ agonists promoted apoptosis of GBM cells, and mechanistic studies using RNA sequencing revealed that LY500307 modulated several pathways related to apoptosis, cell cycle, and DNA damage response. Further, LY500307 sensitized GBM cells to several FDA-approved chemotherapeutic drugs including cisplatin, lomustine and temozolomide. LY500307 treatment significantly reduced the in vivo tumor growth and promoted apoptosis of GBM tumors in an orthotopic model and improved the overall survival of tumor-bearing mice in the GL26 syngeneic glioma model. Our results demonstrate that LY500307 has potential as a therapeutic agent for GBM.

Original languageEnglish (US)
Article number24185
JournalScientific Reports
StatePublished - Apr 29 2016

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma'. Together they form a unique fingerprint.

Cite this